Earnings Feed
Start Free
Home/Insiders/Corvese Brian
CB
SEC Insider//CIK 0001393207

Corvese Brian

CIK 00013932073 companiesNEW YORK, NY
SEC Profile

Transactions

50

Companies

3

Filings

19

CIK

0001393207

Recent Transactions

50 trades
  • Award
    MiNK Therapeutics, Inc.$INKT

    Stock Option (Right to Buy)

    2026-01-02+5,395→ 5,395 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Common Stock

    2025-12-01$11.09/sh+1,612→ 50,053 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Stock Option (Right to Buy)

    2025-09-09+3,225→ 3,225 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Common Stock

    2025-09-02$13.86/sh+1,290→ 48,441 total
  • Award
    AGENUS INC$AGEN

    Stock Option

    2025-06-17+30,000→ 30,000 total
  • Award
    AGENUS INC$AGEN

    Stock Option

    2025-06-17+750→ 750 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Common Stock

    2025-06-02$7.17/sh+2,494→ 47,151 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Common Stock

    2025-03-03$8.79/sh+2,033→ 44,657 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Common Stock

    2024-12-01$0.73/sh+24,400→ 426,283 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Common Stock

    2024-09-03$0.82/sh+21,802→ 405,296 total
  • Award
    AGENUS INC$AGEN

    Stock Option

    2024-06-11+750→ 750 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Common Stock

    2024-06-03$0.99/sh+17,967→ 383,494 total
  • Award
    Protagenic Therapeutics, Inc.\new$PTIX

    PTIX Common stock Options

    2024-03-25$1.74/sh+43,750→ 43,750 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Common Stock

    2024-03-01$0.95/sh+18,816→ 365,527 total
  • Award
    AGENUS INC$AGEN

    Stock Option

    2024-02-05+15,000→ 15,000 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Common Stock

    2023-12-01$1.04/sh+17,188→ 346,711 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Common Stock

    2023-09-01$1.46/sh+12,244→ 329,523 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Stock Option (Right to Buy)

    2023-06-14+37,500→ 37,500 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Common Stock

    2023-06-01$1.76/sh+10,157→ 317,505 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Common Stock

    2023-03-01$2.09/sh+8,553→ 307,348 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Common Stock

    2022-12-01$2.61/sh+6,849→ 298,795 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Common Stock

    2022-09-15$2.62/sh+13,646→ 13,646 total
  • Award
    MiNK Therapeutics, Inc.$INKT

    Stock Option (Right to Buy)

    2022-03-09+25,000→ 25,000 total
  • Award
    AGENUS INC$AGEN

    Stock Option (Right to Buy)

    2022-02-04+150,000→ 150,000 total
  • Exercise/Conversion
    AGENUS INC$AGEN

    Restricted Stock Unit

    2021-06-16−16,000→ 16,000 total
  • Exercise/Conversion
    AGENUS INC$AGEN

    Common Stock

    2021-06-16+22,471→ 92,085 total
  • Award
    AGENUS INC$AGEN

    Stock Option

    2021-06-15+100,000→ 100,000 total
  • Award
    AGENUS INC$AGEN

    Stock Option (Right to buy)

    2020-12-17+100,000→ 100,000 total
  • Exercise/Conversion
    AGENUS INC$AGEN

    Restricted Stock Unit

    2020-06-19+21,118→ 0 total
  • Exercise/Conversion
    AGENUS INC$AGEN

    Common Stock

    2020-06-19+21,118→ 69,614 total
  • Award
    AGENUS INC$AGEN

    Stock Option (Right to buy)

    2020-06-16+2,500→ 2,500 total
  • Award
    AGENUS INC$AGEN

    Restricted Stock Unit

    2020-06-16+22,471→ 49,589 total
  • Award
    Protagenic Therapeutics, Inc.\new$PTIX

    PTIX Common stock Options

    2020-02-21+120,000→ 120,000 total
  • Award
    AGENUS INC$AGEN

    Stock Option (Right to buy)

    2019-12-24+75,000→ 75,000 total
  • Award
    AGENUS INC$AGEN

    Stock Option, Right to buy

    2019-06-19+2,500→ 2,500 total
  • Award
    AGENUS INC$AGEN

    Stock Option, Right to buy

    2019-06-19+100,000→ 102,500 total
  • Award
    AGENUS INC$AGEN

    Restricted Stock Unit

    2019-06-19+27,118→ 27,118 total
  • Award
    AGENUS INC$AGEN

    Restricted Stock Unit

    2018-06-20+21,276→ 21,276 total
  • Award
    AGENUS INC$AGEN

    Stock Option, right to buy

    2018-06-20$5.65/sh+37,500→ 37,500 total
  • Exercise/Conversion
    AGENUS INC$AGEN

    Common Stock

    2018-03-31+21,220→ 21,220 total
  • Exercise/Conversion
    AGENUS INC$AGEN

    Restricted Stock Units

    2018-03-31−21,220→ 0 total
  • Award
    Protagenic Therapeutics, Inc.\new$PTIX

    Non-Qualified Stock Options (Right to Buy)

    2017-10-16+95,000→ 95,000 total
  • Award
    AGENUS INC$AGEN

    Stock Option, Right to buy

    2017-06-29$3.91/sh+2,500→ 2,500 total
  • Award
    AGENUS INC$AGEN

    Stock Option, Right to buy

    2017-06-29$3.91/sh+50,000→ 50,000 total
  • Award
    AGENUS INC$AGEN

    Restricted Stock Unit

    2017-03-31+21,220→ 21,220 total
  • Award
    AGENUS INC$AGEN

    Stock Option, Right to Buy

    2017-03-16$4.16/sh+4,166→ 4,166 total
  • Award
    AGENUS INC$AGEN

    Stock Option, right to buy

    2016-06-15$3.91/sh+35,000→ 35,000 total
  • Award
    AGENUS INC$AGEN

    Stock Option, right to buy

    2015-06-25$8.43/sh+18,750→ 18,750 total
  • Award
    AGENUS INC$AGEN

    Stock Option, Right to Buy

    2013-06-13+15,000→ 15,000 total
  • Award
    AGENUS INC$AGEN

    Stock Option, right to buy

    2012-06-14$5.34/sh+15,000→ 34,166 total

Companies

3

Recent Filings

19

Address

149 FIFTH AVENUE, SUITE 500

NEW YORK, NY, 10010

View on SEC.gov